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Abstract
Controversy surrounds the potential clinical importance of oestro-
gen receptor (ER)β in breast cancer, and three recent papers have
sought to resolve this. In the present issue of Breast Cancer
Research Novelli and colleagues explored the significance of ERβ1
expression in 936 breast cancer patients, and they showed diverse
relationships according to lymph node status. A second paper
examined 442 breast cancers in which ERβ1 was an independent
predictor of recurrence, disease-free survival and overall survival.
Finally a third paper showed that ERβ2 was a powerful prognostic
indicator in 757 breast cancers but this was dependent on cellular
location, with nuclear ERβ2 expression predicting good survival
whilst cytoplasmic expression predicted worse outcome. These
papers point to a clinical role for ERβ in breast cancer and shall be
discussed.
Oestrogen receptor (ER)α remains the most important
biomarker in breast cancer as it indicates the likelihood of
patients to benefit from endocrine therapy. The discovery of
ERβ over a decade ago was initially greeted with interest by
the breast cancer community. Its presence indicated that ER
signalling was no longer restricted to ERα, with a real
possibility of using ERβ as an additional prognostic or
predictive marker in breast cancer, complementing ERα. A
number of studies were subsequently published, examining
ERβ mRNA, protein or a combination of both – but many of
these studies suffered from small sample numbers, use of
poorly validated primary antibodies and failure to consider the
potential importance of known ERβ isoforms. This led to
conflicting results, holding back anticipated progress. As a
result, a great deal of scepticism began to surround the
potential importance of ERβ in breast cancer.
ERβ has recently emerged from the shadows with the
concurrent publication of three papers [1-3]. These articles
stand out from previous studies because they examined large
numbers of breast cancers using well validated, readily
available antibodies.
In the present journal, Novelli and colleagues conducted a
prospective immunohistochemical study of ERβ1 in 936
breast cancers [1]. Rather than relying solely on conventional
statistics to define ERβ association with clinicopathological
factors, the authors used two additional statistical approaches:
multiple correspondence analysis, and classification and
regression tree analysis. The former approach analyses
patterns of relationships of several categorical dependent
variables, while the latter is a tree-building technique
developed to reveal complex interactions between predictors
that may be difficult to find using traditional multivariate
techniques. Multiple correspondence analysis showed ERβ1
positivity was associated with more aggressive breast cancer
phenotypes, namely HER2-positive tumours and triple
negative/basal breast cancers that do not express ERα,
progesterone receptor or HER2 – a relationship that has been
observed by others [3,4] (V. Speirs, unpublished observation).
In another recent study, Honma and colleagues showed
ERβ1 was an independent predictor of recurrence, disease-
free survival and overall survival in 442 cases [3]. Although of
mixed ER status, this cohort all received tamoxifen mono-
therapy with ERα–ERβ1+ phenotype tumours having survival
advantage [3]. This observation suggests that the presence
of any ER subtype, provided it is capable of binding ligand,
can modulate an endocrine response.
The axillary lymph node status is an important prognostic
factor in invasive breast cancer. Accordingly, Novelli and
colleagues stratified their cohort into positive and negative
lymph node status and examined the influence of ERβ1
expression on outcome in each cohort [1]. Using the classifi-
cation and regression tree approach and validation by
conventional statistics, ERβ1 expression predicted a high risk
of relapse in the lymph node-positive group. At first glance
these data might seem counterintuitive, given the general
consensus that ERβ1 is a good prognostic factor in breast
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cancer [3,5,6]. The study of Novelli and colleagues differs
from most others, however, in that these patients were
treated with adjuvant chemotherapy, whereas others have
primarily studied patients receiving endocrine therapy. In
lymph node-negative cases, by contrast, ERβ1 predicted a
favourable response to endocrine therapy. These data are
important; although positive node status predicted worse
prognosis, some 30% of node-negative patients go on to
experience relapse – an identification, therefore, of the need
for potential prognostic factors in lymph node-negative cases.
ERβ1 may fulfil a role in this regard.
Finally, it is important to highlight the role of cytoplasmic ERβ
in dictating breast cancer outcome, something that has been
consistently noted in many studies [2,3,7-9]. Shaaban and
colleagues incorporated this into their immunohistochemical
evaluation of ERβ1, ERβ2 and ERβ5 in 757 breast tumours
[2]. In contrast to Novelli and colleagues [1] and Honma and
colleagues [3], ERβ2 was the most significant ERβ isoform in
terms of breast cancer outcome, as it was predictive of
disease-free survival, overall survival and response to hormone
therapy. This group also formally examined the presence of
cytoplasmic ERβ immunoreactivity. Intriguingly, the cellular
location of ERβ2 determined outcome – with nuclear ERβ2
predicting good clinical response, while cytoplasmic ERβ2
expression predicted significantly worse overall survival. This
was confirmed in 322 independent cases.
These studies put ERβ firmly back into the spotlight as a
potentially important player in ER signalling and hormone-
dependent cancer, with not only specific ERβ isoforms
determining outcome but also their precise cellular location.
ERβ isoforms should now be considered in translational arms
of breast cancer trials where their potential clinical role can
be addressed more rigorously.
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